Hetero Healthcare, a part of Hetero Drugs, is setting up three units in Andhra Pradesh, Telangana and Assam to expand its formulations business in the country. The company will manufacture injectables at the Andhra unit and tablets and capsules at Guwahati unit. These three units will add roughly around 20-25 per cent turnover to the company. It will also plans to add new molecules to expand its product portfolios in the Hepatitis, Oncology, and HIV segments. The company is one of the major global suppliers of APIs (including cytotoxics) to the pharmaceutical companies that manufacture formulations and new-generation products in India and abroad. Currently, the company has over 25 manufacturing facilities located in India, China, Russia, Egypt, Mexico and Iran. Since 1993, the company has produced more than 300 APIs with over 60 of them receiving market approvals in the US and Europe. Additionally, the company produces bulk APIs for regulated and semi-regulated markets.
The subsidiary firm, Hetero Healthcare, has strong product portfolios in Hepatitis, HIV and Oncology segments. Last year, Hetero had launched path-breaking Hepatitis C drugs Sofosbuvir along with other patent holders from Gileads.
Company Profile : Hetero Drugs Ltd